Annual report pursuant to Section 13 and 15(d)

STATEMENTS OF STOCKHOLDERS' EQUITY

v3.20.1
STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Class A Preferred Shares
Class A Common Shares
Common Shares
Common Stock Issuable
Additional Paid-in Capital
Accumulated Deficit
Total
Balances at Dec. 31, 2017 $ 0 $ 0 $ 3,000 $ 9,558,000 $ 98,679,000 $ (48,408,000) $ 59,832,000
Balances (in shares) at Dec. 31, 2017 250,000 1,000,000 25,236,255        
Common stock issuable - Founders Agreement $ 0 $ 0 $ 0 2,085,000 0 0 2,085,000
Issuance of common shares - Founders Agreement $ 0 $ 0 $ 0 (9,558,000) 9,558,000 0 0
Issuance of common shares - Founders Agreement (in shares) 0 0 834,756        
Stock-based compensation expenses $ 0 $ 0 $ 0 0 4,960,000 0 4,960,000
Stock-based compensation expenses (in shares) 0 0 496,552        
Exercise of warrants $ 0 $ 0 $ 0 0 181,000 0 181,000
Exercise of warrants (in shares) 0 0 42,620        
Net loss $ 0 $ 0 $ 0 0 0 (30,662,000) (30,662,000)
Balances at Dec. 31, 2018 $ 0 $ 0 $ 3,000 2,085,000 113,378,000 (79,070,000) 36,396,000
Balances (in shares) at Dec. 31, 2018 250,000 1,000,000 26,610,183        
Common stock issuable - Founders Agreement $ 0 $ 0 $ 0 4,923,000 0 0 4,923,000
Issuance of common shares - Founders Agreement $ 0 $ 0 $ 0 (2,085,000) 2,085,000 0 0
Issuance of common shares - Founders Agreement (in shares) 0 0 709,314        
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech $ 0 $ 0 $ 0 0 375,000 0 375,000
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech (in shares) 0 0 108,069        
Issuance of warrants - Horizon Notes $ 0 $ 0 $ 0 0 888,000 0 888,000
Issuance of warrants - Horizon Notes (in shares) 0 0 0        
Conversion of Class A common shares to common shares $ 0 $ 0 $ 0 0 0 0 0
Conversion of Class A common shares to common shares (in shares) 0 (154,615) 154,615        
Issuance of common shares, net of offering costs - At-the-Market Offering $ 0 $ 0 $ 0 0 21,972,000 0 21,972,000
Issuance of common shares, net of offering costs - At-the-Market Offering (in Shares) 0 0 3,506,222        
Issuance of common shares - Equity fee on At-the-Market Offering $ 0 $ 0 $ 0 0 495,000 0 495,000
Issuance of common shares - Equity fee on At-the-Market Offering (in shares) 0 0 87,656        
Issuance of common shares, net of offering costs - Public Offering $ 0 $ 0 $ 1,000 0 29,536,000 0 29,537,000
Issuance of common shares, net of offering costs - Public Offering (in shares) 0 0 7,906,250        
Issuance of common shares - Equity fee on Public Offering $ 0 $ 0 $ 0 0 791,000 0 791,000
Issuance of common shares - Equity fee on Public Offering (in shares) 0 0 197,656        
Stock-based compensation expenses $ 0 $ 0 $ 0 0 2,664,000 0 2,664,000
Stock-based compensation expenses (in shares) 0 0 30,341        
Exercise of warrants $ 0 $ 0 $ 0 0 0 0 0
Exercise of warrants (in shares) 0 0 93,213        
Net loss $ 0 $ 0 $ 0 0 0 (46,389,000) (46,389,000)
Balances at Dec. 31, 2019 $ 0 $ 0 $ 4,000 $ 4,923,000 $ 172,184,000 $ (125,459,000) $ 51,652,000
Balances (in shares) at Dec. 31, 2019 250,000 845,385 39,403,519